These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32986840)

  • 21. Nationwide mammography screening registers: the best way to go for mortality evaluation - but there is no free lunch.
    Skaane P
    Acta Radiol; 2011 Apr; 52(3):235. PubMed ID: 21498355
    [No Abstract]   [Full Text] [Related]  

  • 22. Constant relative survival rates in Sweden and Norway when adjusting for screening-related overdiagnosis.
    Zahl PH; Maehlen J
    Int J Cancer; 2007 May; 120(10):2279; author reply 2280. PubMed ID: 17230530
    [No Abstract]   [Full Text] [Related]  

  • 23. No difference in the prevalence of benign breast changes between women from Ghana and Norway: an autopsy study.
    Stalsberg H; Adjei EK; Owusu-Afriyie O
    Breast Cancer Res Treat; 2015 May; 151(1):177-82. PubMed ID: 25893589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Consensus conference in Norway: clinical mammography is a valuable diagnostic method, but for early recognition mass screening is recommended].
    Lakartidningen; 1989 Mar; 86(13):1186. PubMed ID: 2704279
    [No Abstract]   [Full Text] [Related]  

  • 25. Nationwide population-based Nordic screening mammography registers: the only key to final evaluation?
    Ljung R; Klint A; Holm LE
    Acta Radiol; 2011 Apr; 52(3):247. PubMed ID: 21498358
    [No Abstract]   [Full Text] [Related]  

  • 26. Biases in estimates of overdetection due to mammography screening.
    Zahl PH; Jørgensen KJ; Maehlen J; Gøtzsche PC
    Lancet Oncol; 2008 Mar; 9(3):199-201; author reply 201-2. PubMed ID: 18308246
    [No Abstract]   [Full Text] [Related]  

  • 27. Number of prior negative screening outcomes does not influence future risk of breast cancer.
    Lilleborge M; Falk RS; Hofvind S
    Eur J Epidemiol; 2020 Jun; 35(6):549-556. PubMed ID: 32430839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammography activity in Norway 1983 to 2008.
    Lynge E; Braaten T; Njor SH; Olsen AH; Kumle M; Waaseth M; Lund E
    Acta Oncol; 2011 Oct; 50(7):1062-7. PubMed ID: 21830995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Difficulties in implementing an organized screening program for breast cancer in Brazil with emphasis on diagnostic methods.
    Silva TB; Mauad EC; Carvalho AL; Jacobs LA; Shulman LN
    Rural Remote Health; 2013; 13(2):2321. PubMed ID: 23597169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Does organized mammographic screening reduce the breast cancer mortality?].
    Zahl PH; Strand BH
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):551; author reply 551. PubMed ID: 11961987
    [No Abstract]   [Full Text] [Related]  

  • 31. [Do women receive enough information to make informed choices about breast cancer screening?].
    Hofmann B
    Tidsskr Nor Laegeforen; 2020 Feb; 140(3):. PubMed ID: 32105039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer screening for women in their 40s reduces mortality.
    Printz C
    Cancer; 2021 Feb; 127(4):497. PubMed ID: 33512720
    [No Abstract]   [Full Text] [Related]  

  • 33. [Mammography in Norway].
    Kåresen R; Thoresen SO
    Nord Med; 1995; 110(8-9):224-5. PubMed ID: 7478974
    [No Abstract]   [Full Text] [Related]  

  • 34. Asymptomatic breast cancer in non-participants of the national screening programme in Norway: a confounding factor in evaluation?
    Hoff SR; Klepp O; Hofvind S
    J Med Screen; 2012 Dec; 19(4):177-83. PubMed ID: 23486698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modes of Early Detection of Breast Cancer in Katowice Region, Poland.
    Zejda JE; Kaleta A
    Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32290585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening.
    Hofvind S; Skaane P
    Rofo; 2012 May; 184(5):437-42. PubMed ID: 22426937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating different breast tumor progression models using screening data.
    Westvik ÅS; Weedon-Fekjær H; Mæhlen J; Liestøl K
    BMC Cancer; 2018 Feb; 18(1):209. PubMed ID: 29463227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program.
    Hofvind S; Román M; Sebuødegård S; Falk RS
    J Med Screen; 2016 Dec; 23(4):203-209. PubMed ID: 26940960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-of-life effects of screening mammography in Norway.
    Zahl PH; Kalager M; Suhrke P; Nord E
    Int J Cancer; 2020 Apr; 146(8):2104-2112. PubMed ID: 31254388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women.
    Újhelyi M; Pukancsik D; Kelemen P; Kovács E; Kenessey I; Bak M; Kásler M; Kovács T; Mátrai Z
    Anticancer Res; 2018 Mar; 38(3):1727-1734. PubMed ID: 29491109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.